Stocks · News reference

Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

Oct 9, 2026, 1:21 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 10, 2026, 5:54 AMTanya Rawat
John Moolenaar Urges Defense Department to Add 120 Chinese Schools and Tech Labs to US Research Funding Watchlist
John Moolenaar asks the US Defense Department to add 58 Chinese schools and 62 technology labs to its research funding restrictions list.
AAPL ABBV AMD BULL MRK
BenzingaOct 9, 2026, 3:28 PMBenzinga Newsdesk
UBS Maintains Neutral on AbbVie, Raises Price Target to $275
UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $260 to $275.
ABBV
The Motley FoolOct 9, 2026, 2:30 PMProsper Junior Bakiny
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens
Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments.
ABBV AMGN ABT